CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
+19.75%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$250M
AUM Growth
+$250M
(+48%)
Cap. Flow
+$41.6M
Cap. Flow
% of AUM
16.63%
Top 10 Holdings %
Top 10 Hldgs %
60.98%
Holding
35
New
4
Increased
16
Reduced
4
Closed
2
Top Buys
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$10M |
| 2 |
Illumina
ILMN
|
$5.47M |
| 3 |
Gilead Sciences
GILD
|
$5.31M |
| 4 |
KITE
Kite Pharma, Inc.
KITE
|
$4.92M |
| 5 |
Sangamo Therapeutics
SGMO
|
$4.84M |
Top Sells
| 1 |
AMRS
Amyris Inc.
AMRS
|
$17.5M |
| 2 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
$3.93M |
| 3 |
Pacific Biosciences
PACB
|
$1.42M |
| 4 |
Adverum Biotechnologies
ADVM
|
$1.13M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$988K |
Sector Composition
| 1 | Healthcare | 88.33% |
| 2 | Materials | 0.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
JNCE
26
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $2.25M | 0.83% | 160,000 +30,000 | +23% | +$421K |
|
27
Editas Medicine
EDIT
$231M
| $2.24M | 0.83% | 133,333 | – | – |
|
28
Fate Therapeutics
FATE
$120M
| $1.78M | 0.66% | +550,000 | New | +$1.78M |
|
|
AMRS
29
DELISTED
Amyris Inc.
AMRS
| $1.59M | 0.59% | 500,000 -5,500,000 | -92% | -$17.5M |
|
|
30
Pacific Biosciences
PACB
$393M
| $1.07M | 0.4% | 300,000 -400,000 | -57% | -$1.42M |
|
31
Curis
CRIS
$20.9M
| $161K | 0.06% | 85,000 -145,000 | -63% | -$275K |
|
|
32
Adverum Biotechnologies
ADVM
$64.6M
| – | – | -420,000 | Closed | -$1.13M |
|
33
Myriad Genetics
MYGN
$593M
| – | – | 0 | – | – |
|
34
SPDR S&P Biotech ETF
XBI
$5.07B
| – | – | 0 | – | – |
|
|
MDRX
35
DELISTED
Veradigm Inc. Common Stock
MDRX
| – | – | -310,000 | Closed | -$3.93M |
|